查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
分子肿瘤学诊断市场 - 全球及各地区分析:各产品，各技术，各用途，各癌症类型，各终端用户，各地区 - 分析与预测(2022年～2032年)
市场调查报告书
商品编码
1165598

分子肿瘤学诊断市场 - 全球及各地区分析:各产品，各技术，各用途，各癌症类型，各终端用户，各地区 - 分析与预测(2022年～2032年)

Molecular Oncology Diagnostics Market - A Global and Regional Analysis: Focus on Product, Technology, Application, Cancer Type, End User, and Region - Analysis and Forecast, 2022-2032
出版日期: | 出版商: BIS Research | 英文 264 Pages | 商品交期: 1-5个工作天内

价格

全球分子肿瘤学诊断的市场规模，2021年是36亿2,060万美金。该市场今后预计2022年～至2032年以11.43％的年复合成长率扩大，2032年达到121亿3,050万美元。

本报告提供全球分子肿瘤学诊断市场相关调查，市场概要，以及各产品，各技术，各用途，各癌症类型，各终端用户，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场

第2章 调查手法

第3章 全球分子肿瘤学诊断市场:概要

  • 市场概要
  • 全球分子肿瘤学诊断的市场规模与预测(2021年～2032年)
  • 癌症的全球发生率和盛行率(各类型)
  • COVID-19对分子肿瘤学诊断市场的影响
  • 液态切片的癌症分子诊断
  • 实验室开发检验(LDT)对体外诊断(IVD)
  • 分子肿瘤学诊断市场上伴随式诊断所扮演的角色

第4章 全球分子肿瘤学诊断市场:产业分析

  • 美国的法律必要条件和架构
  • 欧洲的法律必要条件和架构
  • 亚太地区的法律必要条件和架构

第5章 市场动态

  • 概要
  • 影响分析
  • 成长促进因素
  • 阻碍成长的要素
  • 成长机会

第6章 竞争情形

第7章 全球分子肿瘤学诊断市场(各产品)，100万美元，2021年～2032年

  • 概要
  • 套件和化验
  • 设备
  • 软体

第8章 全球分子肿瘤学诊断市场(各技术)，100万美元，2021年～2032年

  • 概要
  • 聚合酵素链锁反应(PCR)
  • 次世代定序(NGS)
  • 免疫组织化学(IHC)
  • 萤光原位杂交(FISH)
  • 流式细胞技术
  • 其他

第9章 全球分子肿瘤学诊断市场(各用途)，100万美元，2021年～2032年

  • 概要
  • 临床诊断
  • 研究

第10章 全球分子肿瘤学诊断市场(各癌症类型)，100万美元，2021年～2032年

  • 概要
    • 固态肿瘤
    • 骨髓恶性肿瘤

第11章 全球分子肿瘤学诊断市场(各终端用户)，100万美元，2021年～2032年

  • 概要
  • 医院及诊断中心
  • 参照实验室
  • 製药公司，生物科技企业
  • 学术研究机关

第12章 地区

  • 概要
  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第13章 企业简介

  • Agilent Technologies, Inc.
  • Abbott.
  • Biocartis NV
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • Danaher.
  • Guardant Health
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Myriad Genetics, Inc.
  • Sysmex Corporation
Product Code: BHP1289SA

“Global Molecular Oncology Diagnostics Market to Reach $12,130.5 Million by 2032.”

Industry Overview

The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032. The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.

Market Lifecycle Stage

Molecular oncology diagnostics play an essential role in the diagnosis and prognosis of different types of cancers and in improving patient outcomes. Over the last decade, cancer treatment and diagnostics has become a major public health concern across the globe. With over 1.5 million instances reported each year, diseases like cancer can have far-reaching implications for individuals as well as a greater influence on the socioeconomic strata. The market for appropriate testing assay kits is expanding rapidly, owing to the increased importance of early diagnosis to minimize further hazards, especially with rates on the rise. The rising global cancer incidence and the growing demand for early detection are expected to drive the growth of the global molecular oncology diagnostics market during the forecast period. This expanded usage of kit and assay, instrument, and software has enabled end customers to describe particular system requirements, prompting suppliers to design more appealing and practical products and molecular diagnostics choices.

Impact

  • The presence of major kit and assay providers of molecular oncology diagnostics has a major impact on the market. For instance, in March 2021, Biocartis NV launched Idylla GeneFusion Assay as a Rapid Lab Workflow Solution for gene fusion testing. This product provides a much faster testing solution for laboratories in comparison to other testing methods, including NGS.
  • Companies such as Bio-Rad Laboratories, Inc., in August 2022, acquired Curiosity Diagnostics. The company acquired all the outstanding shares of the latter from Scope Fluidics, S.A. for its growth in the medical diagnostic and healthcare markets, for a total consideration of up to $170 million. Similarly, in February 2022, Becton and Dickinson Company (BD) acquired Cytogons to gain exclusive access to advanced assays licensed from the EuroFlow Consortium and strengthen BD's leadership position in the molecular oncology diagnostics segment.

Impact of COVID-19

Cancer screening is crucial for early cancer detection; however, COVID-19 slowed the cancer screening infrastructure greatly. Many cancer organizations have championed the idea of suspending cancer screening services to patients to alter the provision of health care resources. According to the declaration of a national emergency in the U.S. on March 13th, 2020, organizations such as the American Cancer Society advised people to put their cancer screening plans on hold until further notice during the COVID-19 outbreak. Cancer screening services have been severely disrupted because of this proposal, as well as other contextual circumstances (e.g., social exclusion measures).

In response to the COVID-19 pandemic and the impact on medical research in the U.S., the National Institutes of Health (NIH) and the National Cancer Institute (NCI) both extended grant application deadlines, laid back reporting requirements, and offer flexibility in how to grant money is spent. COVID-19 drastically reduced fundraising possibilities for cancer-focused charitable research organizations, which provide up to half of all cancer research funding in the U.S. and frequently fund high-risk, high-reward projects even though the national government supported research work and offered medical researchers the flexibility to implement their skill set and knowledge to studying SARSCoV-2.

Market Segmentation:

Segmentation 1: by Product

  • Kits and Assays
  • Instruments
  • Software

Based on products, the global molecular oncology diagnostics market is expected to be dominated by kit and assay. This is due to the high number of applications performed by kits and their ease of integration with other systems.

Segmentation 2: by Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Fluorescence In-Situ Hybridization (FISH)
  • Flow Cytometry
  • Other Technologies

Based on technology, the global molecular oncology diagnostics market is dominated by polymerase chain reaction (PCR). However, next-generation sequencing (NGS) is expected to be the fastest-growing segment in the market. This is because PCR techniques play an important role in targeted NGS sequencing because they allow for the simultaneous production of several NGS libraries and the sequencing of numerous targeted regions.

Segmentation 3: by Application

  • Clinical Diagnostic
  • Research Use

Based on applications, the global molecular oncology diagnostics market is expected to be dominated by the clinical diagnostic segment. This is due to the high usage of technologies such as companion diagnostics and liquid biopsy emerge.

Segmentation 4: by Cancer Type

  • Solid Tumor
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Other Solid Tumors
  • Hematological Malignancy
    • Lymphoma
    • Leukemia
    • Multiple Myeloma
    • Other Hematological Malignancies

Based on cancer type, the global molecular oncology diagnostics market is dominated by solid tumor cancer type, where breast cancer is expected to be the leading segment. The growth of advanced solid tumor testing has mostly focused on the treatment of distinct cancer kinds, indications, and indication subtypes. The hematological malignancy segment is expected to show a fast growth rate during the forecast period.

Segmentation 5: by End User

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Based on end users, global molecular oncology diagnostics was dominated by the hospitals and diagnostic centers segment. The growth of this segment is primarily attributed to the high use of molecular diagnostic tests by hospitals in these fields.

Segmentation 6: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

North America dominated the global market with a revenue of $1,588.6 in 2021. However, the Asia-Pacific region, constituting several emerging economies, is expected to register the highest CAGR of 12.60% during the forecast period 2022-2032.

Recent Developments in the Global Molecular Oncology Diagnostics Market

  • In August 2022, Guardant Health expanded its Guardant Reveal usage, a liquid biopsy test for residual disease detection and recurrence monitoring, to include early-stage breast and lung cancers. It is the only tissue-free test used for colorectal cancer (CRC) and is now available for patients with breast and lung cancer.
  • In December 2021, QIAGEN partnered with Denovo Biopharma to develop a companion diagnostic test for the treatment of diffuse large B-cell lymphoma. This test identified patients expressing Denovo genomic marker 1 (DGM1), which responded to Denovo's investigational cancer drug DB102.
  • In September 2021, Illumina partnered with Merck to develop and commercialize research tests for use in identifying specific cancer genetic mutations used in the assessment of homologous recombination deficiency (HRD).
  • In August 2021, Agilent Technologies, Inc. expanded its CE-IVD marked PD-L1 IHC 22C3 pharmDx assay usage in Europe. This assay was used as an aid in identifying esophageal cancer patients for treatments with KEYTRUDA using a combined positive score.

Demand - Drivers and Limitations

Following are the demand drivers for the global molecular oncology diagnostics market:

  • Rising Incidence of Cancer Cases
  • Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem
  • Growth in Biomarker identification and Transformations in Molecular Techniques

The market is expected to face some limitations due to the following challenges:

  • Lack of Qualified Professionals
  • Opaque Regulatory Framework Delaying the Approval of New Molecular Diagnostic Tests
  • High Cost of Equipment Hindering the Adoption Rate

How can this report add value to an organization?

  • Product/Innovation Strategy: The report considers only product-based companies. The industry is witnessing constant development and product launches with new and innovative upgrades. Additionally, emerging technologies like microarray are also expected to be integrated more into molecular oncology diagnostics soon, which is expected to further boost market growth.
  • Growth/Marketing Strategy: The key components in molecular oncology diagnostics are the kit and assay, instrument, and software. The cost of the kit and assay depends on the number of integrations one wants the system with. However, the software charges usually surpass the cost of instruments and kits and assays that are necessary to ensure the purchase of the right type of instruments and correct integration and placements.
  • Competitive Strategy: The key players in the global molecular oncology diagnostics market analyzed and profiled in the study consist of product-based companies. Moreover, a detailed competitive benchmarking of the players operating in the global molecular oncology diagnostics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations are expected to aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names in this market are:

  • Agilent Technologies, Inc.
  • Abbott.
  • Biocartis NV
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • Danaher.
  • Guardant Health
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Myriad Genetics, Inc.
  • Sysmex Corporation

Table of Contents

1 Market

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion
  • 1.3 Scope of the Study
  • 1.4 Key Questions Answered in the Report

2 Research Methodology

  • 2.1 Global Molecular Oncology Diagnostics Market: Research Methodology
  • 2.2 Primary Data Sources
  • 2.3 Secondary Data Sources
  • 2.4 Market Estimation Model
  • 2.5 Criteria for Company Profiling

3 Global Molecular Oncology Diagnostics Market: Overview

  • 3.1 Market Overview
    • 3.1.1 Evolution of Molecular Cancer Diagnostics and Current Status
  • 3.2 Global Molecular Oncology Diagnostics Market Size and Forecast (2021-2032)
  • 3.3 Global Incidence and Prevalence of Cancer (by Type)
    • 3.3.1 North America
      • 3.3.1.1 Solid Tumor
      • 3.3.1.2 Hematological Malignancy
    • 3.3.2 Europe
      • 3.3.2.1 Solid Tumor
      • 3.3.2.2 Hematological Malignancy
    • 3.3.3 Asia-Pacific
      • 3.3.3.1 Solid Tumor
      • 3.3.3.2 Hematological Malignancy
  • 3.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
    • 3.4.1 Impact on Market Size
  • 3.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
  • 3.6 Laboratory Developed Test (LDT) Vs. In Vitro Diagnostic (IVD)
  • 3.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market

4 Global Molecular Oncology Diagnostics Market: Industry Analysis

  • 4.1 Legal Requirements and Framework in the U.S.
    • 4.1.1 FDA Regulation
    • 4.1.2 CMS Regulation (Reimbursement Scenario)
  • 4.2 Legal Requirements and Framework in Europe
  • 4.3 Legal Requirements and Framework in Asia-Pacific
    • 4.3.1 China
    • 4.3.2 Japan

5 Market Dynamics

  • 5.1 Overview
  • 5.1 Impact Analysis
  • 5.2 Growth Drivers
    • 5.2.1 Rising Incidence of Cancer Cases
    • 5.2.2 Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem
    • 5.2.3 Growth in Biomarker identification and Transformations in Molecular Techniques
  • 5.3 Growth Restraints
    • 5.3.1 Lack of Qualified Professionals
    • 5.3.2 Opaque Regulatory Framework Delaying the Approval of New Molecular Diagnostic Tests
    • 5.3.3 High Cost of Equipment Hindering the Adoption Rate
  • 5.4 Growth Opportunities
    • 5.4.1 Partnerships and Collaborations between Various Healthcare Stakeholders
    • 5.4.2 Upsurge of Next-Generation Ultrasensitive Molecular Diagnostics

6 Competitive Landscape

  • 6.1 Mergers and Acquisitions
  • 6.2 Synergistic Activities
  • 6.3 Product Launch and Approval Activities
  • 6.4 Expansion, Insurance, and Other Key Developments
  • 6.5 Market-Share Analysis
  • 6.6 Growth-Share Analysis

7 Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021-2032

  • 7.1 Overview
  • 7.2 Kits and Assays
  • 7.3 Instruments
  • 7.4 Software

8 Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021-2032

  • 8.1 Overview
  • 8.2 Polymerase Chain Reaction (PCR)
  • 8.3 Next-Generation Sequencing (NGS)
  • 8.4 Immunohistochemistry (IHC)
  • 8.5 Fluorescence In-Situ Hybridization (FISH)
  • 8.6 Flow Cytometry
  • 8.7 Other Technologies

9 Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021-2032

  • 9.1 Overview
  • 9.2 Clinical Diagnostic
  • 9.3 Research Use

10 Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032

  • 10.1 Overview
    • 10.1.1 Solid Tumor
      • 10.1.1.1 Breast Cancer
      • 10.1.1.2 Lung Cancer
      • 10.1.1.3 Colorectal Cancer
      • 10.1.1.4 Prostate Cancer
      • 10.1.1.5 Ovarian Cancer
      • 10.1.1.6 Other Solid Tumors
    • 10.1.2 Hematological Malignancy
      • 10.1.2.1 Lymphoma
      • 10.1.2.2 Leukemia
      • 10.1.2.3 Multiple Myeloma
      • 10.1.2.4 Other Hematological Malignancies

11 Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021-2032

  • 11.1 Overview
  • 11.2 Hospitals and Diagnostic Centers
  • 11.3 Reference Laboratories
  • 11.4 Pharmaceutical and Biotechnology Companies
  • 11.5 Academic and Research Institutes

12 Region

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 France
    • 12.3.3 U.K.
    • 12.3.4 Italy
    • 12.3.5 Spain
    • 12.3.6 Rest-of-Europe
  • 12.4 Asia-Pacific
    • 12.4.1 China
    • 12.4.2 India
    • 12.4.3 Japan
    • 12.4.4 South Korea
    • 12.4.5 Australia
    • 12.4.6 Rest-of-Asia-Pacific
  • 12.5 Rest-of-the-World (RoW)

13 Company Profiles

  • 13.1 Agilent Technologies, Inc.
    • 13.1.1 Company Overview
    • 13.1.2 Role of Agilent Technologies, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.1.3 Key Competitors of the Company
    • 13.1.4 Business Strategies
      • 13.1.4.1 Merger and Acquisition
      • 13.1.4.2 Product Launch/Approval
      • 13.1.4.3 Expansion
    • 13.1.5 Financials
    • 13.1.6 Analyst Perspective
  • 13.2 Abbott.
    • 13.2.1 Company Overview
    • 13.2.2 Role of Abbott. in the Global Molecular Oncology Diagnostics Market
    • 13.2.3 Key Competitors of the Company
    • 13.2.4 Key Customers of the Company
    • 13.2.5 Financials
    • 13.2.6 Key Insights about the Financial Health of the Company
    • 13.2.7 Analyst Perspective
  • 13.3 Biocartis NV
    • 13.3.1 Company Overview
    • 13.3.2 Role of Biocartis NV in the Global Molecular Oncology Diagnostics Market
    • 13.3.3 Key Competitors of the Company
    • 13.3.4 Corporate Strategies
      • 13.3.4.1 Synergistic Activities
    • 13.3.5 Business Strategies
      • 13.3.5.1 Product Launch/Approval
    • 13.3.6 Financials
    • 13.3.7 Analyst Perspective
  • 13.4 Bio-Rad Laboratories, Inc.
    • 13.4.1 Company Overview
    • 13.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.4.3 Key Competitors of the Company
    • 13.4.4 Corporate Strategies
      • 13.4.4.1 Synergistic Activities
    • 13.4.5 Business Strategies
      • 13.4.5.1 Merger and Acquisition
      • 13.4.5.2 Product Launch/Approval
    • 13.4.6 Financials
    • 13.4.7 Analyst Perspective
  • 13.5 F. Hoffmann-La Roche Ltd.
    • 13.5.1 Company Overview
    • 13.5.2 Role of F. Hoffmann-La Roche Ltd. in the Global Molecular Oncology Diagnostics Market
    • 13.5.3 Key Competitors of the Company
    • 13.5.4 Corporate Strategies
      • 13.5.4.1 Synergistic Activities
    • 13.5.5 Business Strategies
      • 13.5.5.1 Product Launch/Approval
      • 13.5.5.2 Expansion
    • 13.5.6 Financials
    • 13.5.7 Analyst Perspective
  • 13.6 QIAGEN N.V.
    • 13.6.1 Company Overview
    • 13.6.2 Role of QIAGEN N.V. in the Global Molecular Oncology Diagnostics Market
    • 13.6.3 Key Competitors of the Company
    • 13.6.4 Key Customers of the Company
    • 13.6.5 Corporate Strategies
      • 13.6.5.1 Synergistic Activities
    • 13.6.6 Business Strategies
      • 13.6.6.1 Merger and Acquisition
      • 13.6.6.2 Product Launch/Approval
    • 13.6.7 Financials
    • 13.6.8 Analyst Perspective
  • 13.7 Thermo Fisher Scientific, Inc.
    • 13.7.1 Company Overview
    • 13.7.2 Role of Thermo Fisher Scientific, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.7.3 Key Competitors of the Company
    • 13.7.4 Corporate Strategies
      • 13.7.4.1 Synergistic Activities
    • 13.7.5 Business Strategies
      • 13.7.5.1 Product Launch/Approval
      • 13.7.5.2 Expansion
    • 13.7.6 Financials
    • 13.7.7 Analyst Perspective
  • 13.8 Danaher.
    • 13.8.1 Company Overview
    • 13.8.2 Role of Danaher. in the Global Molecular Oncology Diagnostics Market
    • 13.8.3 Key Competitors of the Company
    • 13.8.4 Corporate Strategies
      • 13.8.4.1 Synergistic Activities
    • 13.8.5 Financials
    • 13.8.6 Key Insights about the Financial Health of the Company
    • 13.8.7 Analyst Perspective
  • 13.9 Guardant Health
    • 13.9.1 Company Overview
    • 13.9.2 Role of Guardant Health in the Global Molecular Oncology Diagnostics Market
    • 13.9.3 Key Competitors of the Company
    • 13.9.4 Key Customers of the Company
    • 13.9.5 Corporate Strategies
      • 13.9.5.1 Synergistic Activities
    • 13.9.6 Business Strategies
      • 13.9.6.1 Product Launch/Approval
    • 13.9.7 Financials
    • 13.9.8 Key Insights about the Financial Health of the Company
    • 13.9.9 Analyst Perspective
  • 13.1 HTG Molecular Diagnostics, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.10.3 Key Competitors of the Company
    • 13.10.4 Business Strategies
      • 13.10.4.1 Product Launch/Approval
    • 13.10.5 Financials
    • 13.10.6 Key Insights about the Financial Health of the Company
    • 13.10.7 Analyst Perspective
  • 13.11 Illumina, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Role of Illumina, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.11.3 Key Competitors of the Company
    • 13.11.4 Corporate Strategies
      • 13.11.4.1 Synergistic Activities
    • 13.11.5 Business Strategies
      • 13.11.5.1 Merger and Acquisition
    • 13.11.6 Financials
    • 13.11.7 Key Insights about the Financial Health of the Company
    • 13.11.8 Analyst Perspective
  • 13.12 Invivoscribe, Inc.
    • 13.12.1 Company Overview
    • 13.12.2 Role of Invivoscribe, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.12.3 Key Competitors of the Company
    • 13.12.4 Corporate Strategies
      • 13.12.4.1 Synergistic Activities
    • 13.12.5 Business Strategies
      • 13.12.5.1 Product Launch/Approval
    • 13.12.6 Analyst Perspective
  • 13.13 Myriad Genetics, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 Role of Myriad Genetics, Inc. in the Global Molecular Oncology Diagnostics Market
    • 13.13.3 Key Competitors of the Company
    • 13.13.4 Corporate Strategies
      • 13.13.4.1 Synergistic Activities
    • 13.13.5 Business Strategies
      • 13.13.5.1 Product Launch/Approval
    • 13.13.6 Financials
    • 13.13.7 Key Insights about the Financial Health of the Company
    • 13.13.8 Analyst Perspective
  • 13.14 Sysmex Corporation
    • 13.14.1 Company Overview
    • 13.14.2 Role of Sysmex Corporation in the Global Molecular Oncology Diagnostics Market
    • 13.14.3 Key Competitors of the Company
    • 13.14.4 Corporate Strategies
      • 13.14.4.1 Synergistic Activities
    • 13.14.5 Business Strategies
      • 13.14.5.1 Product Launch/Approval
      • 13.14.5.2 Expansion
    • 13.14.6 Financials
    • 13.14.7 Key Insights about the Financial Health of the Company
    • 13.14.8 Analyst Perspective

List of Figures

  • Figure 1: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019
  • Figure 2: Global Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 3: Global Molecular Oncology Diagnostics Market, Dynamics
  • Figure 4: Share of Key Market Strategies and Developments, January 2019-October 2022
  • Figure 5: Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 Vs. 2032
  • Figure 6: Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 Vs. 2032
  • Figure 7: Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 Vs. 2032
  • Figure 8: Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 Vs. 2032
  • Figure 9: Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 Vs. 2032
  • Figure 10: Global Molecular Diagnostics Market (by Region), $Million, 2021 Vs. 2032
  • Figure 11: Role of Diagnostics in Healthcare
  • Figure 12: Global Molecular Oncology Diagnostics Market Segments
  • Figure 13: Global Molecular Oncology Diagnostics Market: Methodology
  • Figure 14: Primary Research Methodology
  • Figure 15: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 16: Top-Down Approach (Segment-Wise Analysis)
  • Figure 17: Global Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 18: Solid Tumor Prevalence and Incidence Data in Europe, 2020
  • Figure 19: Hematological Malignancy Prevalence and Incidence Data in North America, 2020
  • Figure 20: Solid Tumor Prevalence and Incidence Data in Europe, 2020
  • Figure 21: Hematological Malignancy Prevalence and Incidence Data in Europe, 2020
  • Figure 22: Solid Tumor Prevalence and Incidence Data in Asia-Pacific, 2020
  • Figure 23: Hematological Malignancy Prevalence and Incidence Data in Asia-Pacific, 2020
  • Figure 24: Global Molecular Oncology Diagnostics Market, $Million, 2019-2021
  • Figure 25: Prominent FDA-Approved CDx Tests for Molecular Oncology Diagnostics
  • Figure 26: FDA Guidelines for CDx Approval
  • Figure 27: Criteria for CMS Coverage/Reimbursement
  • Figure 28: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 29: Workflow for Medical Device Regulations
  • Figure 30: Global Molecular Diagnostics Market: Market Dynamics
  • Figure 31: Likert Scale
  • Figure 32: Impact Analysis of Market Drivers and Challenges on the Global Molecular Oncology Diagnostics Market
  • Figure 33: Global Distribution of Cases and Deaths (by Cancer Type), 2020
  • Figure 34: Global Incidence for Cancer Types (2017-2019)
  • Figure 35: Product Upgradations and Technological Advancements, 2019-2022
  • Figure 36: Synergistic Activities, 2019-2021
  • Figure 37: Share of Key Developments and Strategies, January 2019-October 2022
  • Figure 38: Share of Mergers and Acquisitions (by Company), January 2019-October 2022
  • Figure 39: Share of Synergistic Activities (by Company), January 2019-October 2022
  • Figure 40: Share of Product Launch and Approval Activities (by Company), January 2019-October 2022
  • Figure 41: Share of Expansion, Insurance, and Other Key Developments (by Company), January 2019-October 2022
  • Figure 42: Market-Share Analysis for the Global Molecular Oncology Diagnostics Market, $Million, 2021
  • Figure 43: Growth-Share Analysis of Global Molecular Oncology Diagnostics Market (by Technology), 2021-2032
  • Figure 44: Global Molecular Oncology Diagnostics Market (by Product)
  • Figure 45: Share of Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 and 2032
  • Figure 46: Global Molecular Oncology Diagnostics Market (Kits and Assays), $Million, 2021-2032
  • Figure 47: Global Molecular Oncology Diagnostics Market (Instruments), $Million, 2021-2032
  • Figure 48: Global Molecular Oncology Diagnostics Market (Software), $Million, 2021-2032
  • Figure 49: Global Molecular Oncology Diagnostics Market (by Technology)
  • Figure 50: Share of Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 and 2032
  • Figure 51: Global Molecular Oncology Diagnostics Market (Polymerase Chain Reaction), $Million, 2021-2032
  • Figure 52: Global Molecular Oncology Diagnostics Market (Next-Generation Sequencing), $Million, 2021-2032
  • Figure 53: Global Molecular Oncology Diagnostics Market (Immunohistochemistry), $Million, 2021-2032
  • Figure 54: Global Molecular Oncology Diagnostics Market (Fluorescence In-Situ Hybridization), $Million, 2021-2032
  • Figure 55: Global Molecular Oncology Diagnostics Market (Flow Cytometry), $Million, 2021-2032
  • Figure 56: Global Molecular Oncology Diagnostics Market (Other Technologies), $Million, 2021-2032
  • Figure 57: Share of Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 and 2032
  • Figure 58: Global Molecular Oncology Diagnostics Market (Clinical Diagnostic), $Million, 2021-2032
  • Figure 59: Global Molecular Oncology Diagnostics Market (Research Use), $Million, 2021-2032
  • Figure 60: Global Molecular Oncology Diagnostics Market (by Cancer Type)
  • Figure 61: Share of Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 and 2032
  • Figure 62: Global Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021 and 2032
  • Figure 63: Global Molecular Oncology Diagnostics Market (Breast Cancer), $Million, 2021-2032
  • Figure 64: Global Molecular Oncology Diagnostics Market (Lung Cancer), $Million, 2021-2032
  • Figure 65: Global Molecular Oncology Diagnostics Market (Colorectal Cancer), $Million, 2021-2032
  • Figure 66: Global Molecular Oncology Diagnostics Market (Prostate Cancer), $Million, 2021-2032
  • Figure 67: Global Molecular Oncology Diagnostics Market (Ovarian Cancer), $Million, 2021-2032
  • Figure 68: Global Molecular Oncology Diagnostics Market (Other Solid Tumors), $Million, 2021-2032
  • Figure 69: Global Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021 and 2032
  • Figure 70: Global Molecular Oncology Diagnostics Market (Lymphoma), $Million, 2021-2032
  • Figure 71: Global Molecular Oncology Diagnostics Market (Leukemia), $Million, 2021-2032
  • Figure 72: Global Molecular Oncology Diagnostics Market (Multiple Myeloma), $Million, 2021-2032
  • Figure 73: Global Molecular Oncology Diagnostics Market (Other Hematological Malignancies), $Million, 2021-2032
  • Figure 74: Share of Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 and 2032
  • Figure 75: Global Molecular Oncology Diagnostics Market (Hospitals and Diagnostic Centers), $Million, 2021-2032
  • Figure 76: Global Molecular Oncology Diagnostics Market (Reference Laboratories), $Million, 2021-2032
  • Figure 77: Global Molecular Oncology Diagnostics Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
  • Figure 78: Global Molecular Oncology Diagnostics Market (Academic and Research Institutes), $Million, 2021-2032
  • Figure 79: Global Molecular Oncology Diagnostics Market Snapshot (by Region), $Million, 2021-2032
  • Figure 80: Global Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032
  • Figure 81: North America Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 82: North America: Market Dynamics
  • Figure 83: North America Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
  • Figure 84: U.S. Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 85: U.S. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 86: U.S. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 87: U.S. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 88: Canada Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 89: Canada Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 90: Canada Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 91: Canada Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 92: Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 93: Europe: Market Dynamics
  • Figure 94: Europe Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
  • Figure 95: Germany Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 96: Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 97: Germany Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 98: Germany Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 99: France Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 100: France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 101: France Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 102: France Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 103: U.K. Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 104: U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 105: U.K. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 106: U.K. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 107: Italy Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 108: Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 109: Italy Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 110: Italy Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 111: Spain Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 112: Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 113: Spain Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 114: Spain Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 115: Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 116: Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 117: Rest-of-Europe Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 118: Rest-of-Europe Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 119: Asia-Pacific Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032
  • Figure 120: Asia-Pacific: Market Dynamics
  • Figure 121: Asia-Pacific Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
  • Figure 122: China Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 123: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 124: China Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 125: China Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 126: India Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 127: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 128: India Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 129: India Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 130: Japan Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 131: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 132: Japan Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 133: Japan Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 134: South Korea Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 135: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 136: South Korea Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 137: South Korea Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 138: Australia Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 139: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 140: Australia Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 141: Australia Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 142: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 143: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
  • Figure 144: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
  • Figure 145: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032
  • Figure 146: Rest-of-the-World Molecular Oncology Diagnostics Market, $Million, 2021-2032
  • Figure 147: Total Number of Companies Profiled
  • Figure 148: Agilent Technologies, Inc.: Product Portfolio
  • Figure 149: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 150: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 151: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 152: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
  • Figure 153: Abbott.: Overall Product Portfolio
  • Figure 154: Abbott.: Overall Financials, $Million, 2019-2021
  • Figure 155: Abbott.: Revenue (by Segment), $Million, 2019-2021
  • Figure 156: Abbott.: Revenue (by Region), $Million, 2019-2021
  • Figure 157: Abbott.: R&D Expenditure, $Million, 2019-2021
  • Figure 158: Biocartis NV.: Product Portfolio
  • Figure 159: Biocartis NV: Overall Financials, $Million, 2019-2021
  • Figure 160: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 161: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 162: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 163: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 164: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 165: F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Figure 166: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2019-2021
  • Figure 167: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2019-2021
  • Figure 168: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2019-2021
  • Figure 169: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2019-2021
  • Figure 170: QIAGEN N.V.: Product Portfolio
  • Figure 171: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
  • Figure 172: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
  • Figure 173: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
  • Figure 174: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
  • Figure 175: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 176: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 177: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 178: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 179: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 180: Danaher.: Product Portfolio
  • Figure 181: Danaher.: Overall Financials, $Million, 2019-2021
  • Figure 182: Danaher.: Revenue (by Segment), $Million, 2019-2021
  • Figure 183: Danaher.: Revenue (by Region), $Million, 2019-2021
  • Figure 184: Danaher.: R&D Expenditure, $Million, 2019-2021
  • Figure 185: Guardant Health: Overall Product Portfolio
  • Figure 186: Guardant Health: Overall Financials, $Million, 2019-2021
  • Figure 187: Guardant Health: Revenue (by Segment), 2019-2021
  • Figure 188: Guardant Health: R&D Expenditure, $Million, 2019-2021
  • Figure 189: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
  • Figure 190: HTG Molecular Diagnostics, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 191: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2019-2021
  • Figure 192: HTG Molecular Diagnostics, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 193: Illumina, Inc.: Overall Product Portfolio
  • Figure 194: Illumina, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 195: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 196: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 197: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 198: Invivoscribe, Inc.: Overall Product Portfolio
  • Figure 199: Myriad Genetics, Inc.: Product Portfolio
  • Figure 200: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 201: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 202: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 203: Sysmex Corporation: Overall Product Portfolio
  • Figure 204: Sysmex Corporation: Overall Financials, $Million, 2019-2021
  • Figure 205: Sysmex Corporation: Revenue (by Region), $Million, 2019-2021
  • Figure 206: Sysmex Corporation: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Biomarkers for Different Cancer Types
  • Table 2: Cost of Liquid Biopsy Based NGS Diagnostic Kits
  • Table 3: Companies Providing Kits and Assays for Molecular Oncology Diagnostics